Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 15/20 | 0.61 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.47 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.47 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.47 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.47 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.47 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.43 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.43 |
| ▸ | MC4R | P32245 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | WDR5 | P61964 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2833198 | 0.90 | CFTR (0.75) | CFTRGABRA1GABRB1GABRA5GABRA3 | |
| SCHEMBL397785 | 0.86 | CFTR (0.81) | CFTRGABRA1GABRB1GABRA5GABRA3 | |
| SCHEMBL2862971 | 0.85 | CFTR (0.59) | CFTRGABRA1GABRB1GABRA5GABRA3 | |
| SCHEMBL2967643 | 0.83 | CFTR (0.65) | CFTRGABRA1GABRB1GABRA5GABRA3 | |
| SCHEMBL2978687 | 0.82 | CFTR (0.63) | CFTRGABRA1GABRB1GABRA5GABRA3 | |
| SCHEMBL14780618 | 0.78 | CFTR (0.56) | CFTRGABRA1GABRB1GABRA5GABRA3 | |
| SCHEMBL2979468 | 0.78 | CFTR (0.61) | CFTRGABRA1GABRB1GABRA5GABRA3 | |
| SCHEMBL2832397 | 0.78 | TRPV1 (0.48) | CFTRWDR5 | |
| SCHEMBL2833223 | 0.77 | CFTR (0.59) | CFTRGABRA1GABRB1GABRA5GABRA3 | |
| SCHEMBL13229687 | 0.77 | CFTR (0.56) | CFTRGABRA1GABRB1GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2201010-B1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2013-11-06 | — | — | EP | claimed |
| US-8748612-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-06-10 | — | — | US | disclosed |
| EP-2201010-B1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2013-11-06 | — | — | EP | disclosed |
| US-20130178496-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2013-07-11 | — | — | US | disclosed |
| US-8410132-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-02 | — | — | US | disclosed |
| US-20130018070-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-17 | — | — | US | disclosed |
| US-8188283-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-20100261750-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178496-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, ABCB1, ABCC1 | CFTR 1/4885GABRA1 923/4885GABRB1 249/4885 |
| US-20130018070-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, ABCB1, ABCC1 | CFTR 1/4885GABRA1 923/4885GABRB1 249/4885 |
| US-20100261750-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | CFTR, ABCB1, ABCC1 | CFTR 1/4885GABRA1 923/4885GABRB1 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.